Additional Details

  • Platform Clinical Study for Conquering Scleroderma

    Duke University Medical Center
    Durham NC. 27710
    View Details

  • Platform Clinical Study for Conquering Scleroderma

    University of California, Los Angeles (UCLA) Ronald Reagan Medical Center
    Los Angeles CA. 90095-7436
    View Details

  • Platform Clinical Study for Conquering Scleroderma

    Stanford University Medical Center
    Palo Alto CA. 94305
    View Details

  • Physical Activity and Quality of Life in Fibrotic Lung Diseases After Initiating Anti-fibrotic Therapy and Pulmonary Rehabilitation

    University of South Florida/ Tampa General Hospital
    Tampa FL. 33606
    View Details

  • Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

    HonorHealth Research Institute
    Scottsdale AZ. 85258
    View Details

  • Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

    Temple University Hospital-Temple Lung Center
    Philadelphia PA. 19140
    View Details

  • Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

    University of Alabama at Birmingham
    Birmingham AL. 35294
    View Details

  • Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

    Central Florida Pulmonary Group, P.A. (CFPG) - Downtown Orlando
    Orlando FL. 32803-5727
    View Details

  • Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

    University of Texas Southwestern Medical Center
    Dallas TX. 75235-6243
    View Details

  • Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

    University of Oklahoma Health Sciences Center (OUHSC)
    Oklahoma City OK. 73104-5417
    View Details

  • Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

    Southeastern Research Center
    Winston-Salem NC. 27103-4007
    View Details

  • Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

    Metroplex Pulmonary and Sleep Center
    McKinney TX. 75069-1898
    View Details

  • Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

    Florida Lung Asthma and Sleep Specialist
    Celebration FL. 34747-1818
    View Details

  • Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

    Bogan Sleep Consultants, LLC
    Columbia SC. 29201-2953
    View Details

  • Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

    Keck School of Medicine of USC
    Los Angeles CA. 90033
    View Details

  • Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

    Research Centers of America
    McKinney TX. 75071
    View Details

  • Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)

    Temple University
    Philadelphia PA. 19140
    View Details

  • Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)

    UNC Chapel Hill
    Chapel Hill NC. 27514
    View Details

  • Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)

    Pulmonary & Sleep Specialists
    Dickson TN. 37055
    View Details

  • Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)

    Avera Research Institute
    Sioux Falls SD. 57108
    View Details